Turning Point Therapeutics to Participate in 38th Annual J.P. Morgan Healthcare Conference

NEXT STORY
ContraFect Corporation Prices Approximately $10 Million Public Offering of Common Stock
PREV STORY
Roche concludes acquisition of Spark Therapeutics, Inc. to strengthen presence in gene therapy
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Orion Corporation: Managers’ transactions – Kari Jussi Aho

author_avatar
NASDAQ Market News

Cue Biopharma to Present at the Cowen 41st Annual Health Care Conference

author_avatar
NASDAQ Market News

Phase III IMpassion130 study showed Roche’s Tecentriq plus Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer

First Phase III immunotherapy study to demonstrate a statistically significant improvement in progression-free survival ...

author_avatar
NASDAQ Market News